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Epidermal growth factor (EGF) and ﬁbronectin are known to play an important role in wound healing. In this study,
we demonstrated that EGF upregulates the expression of ﬁbronectin mRNA and protein in human dermal
ﬁbroblasts. Actinomycin D, an RNA synthesis inhibitor, signiﬁcantly blocked basal mRNA expression, but the
addition of EGF compensated the blockage. Cycloheximide, a protein synthesis inhibitor, did not block this
upregulation by EGF. In addition, the treatment with EGF signiﬁcantly reduced the degradation rate of ﬁbronectin
mRNA. But EGF did not increase ﬁbronectin promoter activity. EGF-mediated induction of ﬁbronectin expression
was inhibited by the treatment of ﬁbroblasts with protein kinase C (PKC) inhibitor, Calphostin C and Rottlerin. The
transfection of a dominant-negative mutant of PKCd into ﬁbroblasts signiﬁcantly reduced the induction of
ﬁbronectin protein expression by EGF. EGF enhanced PKCd protein expression and also translocated PKCd to the
membrane. Rottlerin blocked the EGF-mediated reduction of mRNA degradation rate. These results indicate that
EGF-mediated induction of ﬁbronectin expression occurs at the post-transcriptional level and involves PKCd
signaling pathway.
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Fibronectin is a high-molecular-weight glycoprotein present
at cell surfaces, in tissues, in the blood, and in other body
fluids (Mosher, 1980; Ruoslahti et al, 1981). Fibronectin is a
dimer of two polypeptide chains with molecular weights
close to 220 000 (Mosesson et al, 1975). Fibronectin
interacts with collagens (Dessau et al, 1978), fibrinogen
(Ruoslahti and Vaheri, 1975), actin (Keski-Oja et al, 1980),
and cell surfaces (Pearlstein, 1976). Fibronectin is a family
of extracellular matrix and plasma glycoproteins that can
promote cell migration, attachment, and spreading. Thus,
fibronectin plays several important roles in wound healing,
functioning to promote clot formation, development of
granulation tissue, and re-epithelialization (Grinell, 1984;
Clark, 1990).
The first stage of wound healing, inflammation, involves
rapid deposition and polymerization of fibrin (Dvorak et al,
1988). Plasma fibronectin binds and can be covalently
cross-linked with fibrin to form a fibrous clot structure that
promotes migration and attachment of leukocytes and
fibroblasts (Postlehwaite et al, 1981; Clark, 1988; Dvorak
et al, 1988). A 120-kd fibronectin fragment is also chemotactic
for monocytes, implying further involvement in macrophage
recruitment (Clark, 1988). Fibroblasts subsequently migrate
into the wounds space and produce additional fibronectin,
which is assembled into a well-ordered, disulfide cross-
linked, provisional matrix (Kurkine et al, 1980; Grinell et al,
1981). Fibronectin is able to interact with other matrix
proteins and macromolecules, and thus promotes granula-
tion tissue formation (Hynes, 1985). Re-epithelialization is
accomplished as epidermal cells migrate over the provi-
sional matrix provided by granulation tissue and re-
establish the basement membrane. This migration depends
at least partially on fibronectin which binds to the
keratinocytes through its binding receptor such as a5b1
integrin (Larjava et al, 1993).
Epidermal growth factor (EGF) is a single-chain poly-
peptide having a molecular weight of about 6 kDa. EGF
receptors can be detected both in human fibroblasts
(Hollenberg and Cuatrecasas, 1973) and in a wide variety
of mammalian tissues (Covelli et al, 1972; Frati et al, 1972).
EGF triggers many biological responses, including cell
proliferation and differentiation (Carpenter and Cohen,
1990). In addition, EGF has been shown to induce the
reorganization of the actin cytoskeleton, and the EGF
receptors have been found to be associated with actin
filaments (Roy et al, 1989; van Belzen et al, 1990; den
Hartigh et al, 1992; Gronowski and Bertics, 1995). In this
regard, EGF has been reported to stimulate rapid cell
rounding, extensive membrane ruffling, extension of filopo-
dia, retraction of cells from the substratum (Chinkers et al,
1981), extensive cortical actin polymerization, and depoly-
merization of actin stress fibers (Schlessinger and Geiger,
1981; Rijken et al, 1991). Moreover, numerous studies have
Abbreviations: EGF, epidermal growth factor; ERK, extracellular
signal-related kinase; GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; MAPK, mitogen-activated protein kinase; PKC, protein
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shown that activation of the EGF receptor leads to
increased cell motility (Blay and Brown, 1985; Basson et al,
1992; Chen et al, 1993; Matthay et al, 1993; Klemke et al,
1994; Fujii et al, 1995), thereby supporting a role for the EGF
receptor in normal development and pathophysiological
events such as tumor cell invasion and metastasis, and
wound healing. Studies using exogenous application of
EGF have reported an enhancement of epithelialization
during wound repair (Brown et al, 1989; Carpenter and
Cohen, 1990). In addition, it was reported that exogenous
EGF had positive effects on dermal components as well as
epidermal components (Nanney, 1990). It was also reported
that EGF showed stimulatory effects in granulation tissue
models of wound repair (Buckley et al, 1985).
Thus, many studies have suggested that both fibronectin
and EGF promote wound repair at its various stages. (Laato
et al (1989) reported that EGF increased fibronectin mRNA
in rat granulation fibroblasts). But the mechanism of EGF-
mediated upregulation of fibronectin is yet to be elucidated.
Here we focused on how EGF regulates fibronectin
production in human dermal fibroblasts.
Results
Fibronectin secretion in human dermal ﬁbroblasts is
upregulated by EGF In this study, we investigated the
effects of EGF on the expression of fibronectin in human
dermal fibroblasts. First, we investigated the concentration
dependency of the effect of EGF on the expression of
fibronectin. Human dermal fibroblasts were cultured until
they were confluent, and then incubated for an additional
24 h under conditions of serum starvation. Cells were sub-
sequently incubated for 24 h in the presence or absence of
the indicated doses of EGF or transforming growth factor
(TGF)a. The loading amount of the culture media was
adjusted by the protein concentration of cell lysates. The
fibronectin protein level was elevated maximally (2.2-fold)
by treatment with 20 ng per mL EGF, but was less elevated
in response to treatment with higher concentrations of 50 ng
per mL EGF. TGFa, which has been reported to activate EGF
receptor, also increased fibronectin secretion into media
(Fig 1A). In addition, the expression level of fibronectin
mRNA was elevated maximally (1.9-fold) by treatment with
20 ng per mL EGF (Fig 1B and C). Next, to examine the time
dependency of the effect of EGF on the expression of
fibronectin, cells were incubated for the indicated times in
the presence or absence of 20 ng per mL EGF. The loading
amount of the culture media was adjusted by the protein
concentration of cell lysates. The fibronectin protein level
was slightly elevated after the stimulation with EGF for 12 h
and markedly increased (2.3-fold) after 48 h in comparison
with the level in control cells (Fig 2A). To determine whether
the EGF-mediated induction of fibronectin protein expres-
sion was correlated with an increase of fibronectin mRNA,
human dermal fibroblasts were incubated in the presence or
absence of 20 ng per mL EGF under the same conditions,
and mRNA expression was analyzed by northern blotting.
The expression of fibronectin mRNA was elevated after the
stimulation with EGF for 6 h, and markedly increased (1.9-
fold) after 24 h in comparison with the control level (Fig 2B
and C). Thus, the effect of EGF on the fibronectin protein
paralleled that on the mRNA level.
Mechanisms of EGF-mediated ﬁbronectin upregula-
tion To determine whether the EGF-mediated fibronectin
upregulation requires protein synthesis, human dermal
fibroblasts were incubated with cycloheximide before EGF
treatment. The addition of cycloheximide alone did not
cause cell death. Instead, it increased the basal fibronectin
mRNA level (1.6-fold). EGF induced an increase in fibro-
nectin mRNA expression in the presence of cycloheximide
similar to that which occurred in the absence of cyclohex-
imide (Fig 3A and B). Thus, EGF-mediated upregulation of
fibronectin is independent of new protein synthesis. More-
over, to determine whether the upregulation of fibronectin
expression was due to increased RNA synthesis, the effects
of EGF on newly transcribed RNA were examined by the
treatment of human dermal fibroblasts with actinomycin D.
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Figure1
Concentration-dependent effects of epidermal growth factor (EGF)
on the fibronectin level. Human dermal fibroblasts were serum
starved for 24 h and incubated in the absence or presence of indicated
doses of EGF or transformation growth factor (TGF)a for an additional
24 h. (A) Medium (adjusted by the protein concentration of the cell
lysates) was subjected to immunoblotting with anti-fibronectin anti-
bodies. Levels of b-actin are shown as a loading control. One
representative result of three independent experiments is shown. (B)
Northern blot analysis was performed to evaluate fibronectin mRNA
expression. Levels of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA are shown as a loading control. (C) Fibronectin mRNA
levels quantitated by scanning densitometry and corrected for the
levels of GAPDH in the same samples are shown relative to the level in
untreated cells (1.0). Data are expressed as the mean  SD of three
independent experiments. po0.05, as compared with the value in
untreated cells.
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The addition of actinomycin D alone did not cause cell
death and decreased the basal fibronectin mRNA level. EGF
induced an increase in fibronectin mRNA expression even in
the cells treated with actinomycin D, in contrast to the
decreased mRNA level when treated only with actinomycin
D (Fig 3A and B). These findings indicate that EGF may
contribute to the increase of the stability of fibronectin
mRNA. Next we determined whether the induction of
fibronectin expression by EGF is also regulated at the level
of transcription. We used the fibronectin promoter-pGL3ba-
sic (508/þ18) to determine whether EGF induces the
fibronectin gene at the transcriptional level. The fibronectin
promoter activity in the cells treated with EGF (5–100 ng per
mL) was not significantly different from that observed in un-
treated cells, whereas the promoter activity in the cells
treated with TGF-b (2 ng per mL) significantly increased
(2.2-fold) (Fig 4).
Taken together, these results indicate that EGF induces
an increase of fibronectin mRNA mainly at the post-
transcriptional level by upregulating its stability, and this
induction is independent of new protein synthesis or gene
transcription.
Signaling pathway involved in the EGF-mediated ﬁbro-
nectin induction Since the PKC, extracellular signal-
related kinase (ERK), and p38 mitogen-activated protein
kinase (MAPK) are involved in the signaling by EGF, we
investigated which signaling pathway is mainly involved in
the EGF-mediated fibronectin induction. The pre-treatment
of cells with Calphostin C (non-selective PKC inhibitor)
or Rottlerin, which more potently inhibits PKCd than any
other PKC isoform, blocked EGF-mediated upregulation of
fibronectin mRNA, but Go¨6976 (selective PKCa inhibitor),
PD98059 (MEK inhibitor), or SB203580 (p38 MAPK inhibitor)
did not (Fig 5A and B). The specificity and effectiveness of
PD98059 and SB203580 as an inhibitor of MEK and p38
MAPK was well established in our previous studies (Ihn and
Tamaki, 2000, 2002; Ihn et al, 2002). These results indicated
that EGF induces fibronectin expression via PKC, especially
PKCd, signaling pathway, but that activation of ERK or p38
MAPK is unnecessary for EGF-mediated upregulation of
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Figure 2
Time course of fibronectin expression levels in dermal fibroblasts
stimulated by epidermal growth factor (EGF). Human dermal
fibroblasts were serum starved for 24 h and incubated in the presence
of 20 ng per mL EGF for the indicated times. (A) Medium samples
(adjusted by the protein concentration of the cell lysates) were
subjected to immunoblotting using anti-fibronectin antibodies. Levels
of b-actin are shown as a loading control. One representative result of
three independent experiments is shown. (B) Northern blot analysis
was performed to evaluate fibronectin mRNA expression. Levels of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA are
shown as a loading control. One representative result of three
independent experiments is shown. (C) Fibronectin mRNA levels
quantitated by scanning densitometry and corrected for the levels of
GAPDH in the same samples are shown relative to the level at 0 h (1.0).
Data are expressed as the mean  SD of three independent experi-
ments. po0.05, as compared with the value in untreated cells.
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Figure3
Effects of actinomycin D or cycloheximide on epidermal growth
factor (EGF)-mediated fibronectin upregulation. Human dermal
fibroblasts were serum starved for 24 h and incubated in the absence
or presence of 400 ng per mL actinomycin D or 10 mg per mL
cycloheximide, with or without 20 ng per mL EGF, for 12 h. (A) Northern
blot analysis was performed to evaluate fibronectin mRNA expression.
Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA are shown as a loading control. One representative result of
three independent experiments is shown. (B) Fibronectin mRNA levels
quantitated by scanning densitometry and corrected for the levels of
GAPDH in the same samples are shown relative to the level in untreated
cells (1.0). Data are expressed as the mean  SD of three independent
experiments. po0.05, as compared with the value in untreated cells.
#po0.05, as compared with the value in the cells treated only with
actinomycin D. wpo0.05, as compared with the value in the cells
treated only with cycloheximide.
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fibronectin. Moreover, we examined the concentration-
dependent effect of Calphostin C or Rottlerin on upregula-
tion of fibronectin expression by EGF. Calphostin C or
Rottlerin blocked EGF-mediated upregulation of fibronectin
mRNA in a concentration-dependent manner (Fig 5C and D).
PKCd inhibitors also inhibit EGF-mediated ﬁbronectin
protein expression Human dermal fibroblasts were pre-
treated with Calphostin C or Rottlerin for 1 h, and then
added with EGF (20 ng per mL). At 48 h after the addition of
EGF, fibronectin secretion into medium was determined by
immunoblotting. The loading amount of the culture media
was adjusted by the number of cells. Calphostin C or
Rottlerin blocked EGF-mediated upregulation of fibronectin
secretion in a concentration-dependent manner (Fig 6A).
Next, we examined fibronectin protein expression by the
cells transfected with dn mutant form of PKCd. Human
dermal fibroblasts were transiently transfected with either
empty vector or dn PKCd. The specificity and effectiveness
of dn PKCd was well established in previous studies (Li et al,
1995, 1996). After incubation overnight, the transfected
cells were treated or untreated with 20 ng per mL EGF for 48
h. Medium samples (adjusted by counting cell numbers)
were subjected to immunoblotting with anti-fibronectin
antibodies. The cells transfected with dn PKCd inhibited
the EGF-mediated induction of fibronectin protein expres-
sion, but the cells transfected with the vector did not
change the effect of EGF (Fig 6B).
EGF induces an increase in the level of PKCd but not in
that of PKCa and PKCe Since PKC inhibitors inhibit the
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Figure 4
Epidermal growth factor (EGF)-mediated induction of the fibro-
nectin promoter activity in human dermal fibroblasts. Human
dermal fibroblasts were transiently transfected with the fibronectin
promoter-pGL3LUC (508/þ 18). After incubation for 24 h, the cells
were stimulated with EGF or transformation growth factor (TGF)b at the
indicated doses for 18 h. EGF or TGFb induction was determined as the
fold increase in the luciferase activity relative to that in untreated cells
(1.0). Data are expressed as the mean  SD of three independent
experiments. po0.05, as compared with the value in untreated cells.
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Figure5
Effects of Calphostin C, Rottlerin, Go¨6976, PD98059, and SB203580
on the epidermal growth factor (EGF)-induced fibronectin. Human
dermal fibroblasts were serum starved for 24 h and pre-treated with 50
mM Calphostin C, 3 mM Rottlerin, 50nM Go¨6976, 30 mM PD98059, 10
mM SB203580 for 1 h prior to the addition of 20 ng per mL of EGF for 24
h. (A) Northern blot analysis was performed to evaluate fibronectin
mRNA expression. Levels of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA are shown as a loading control. One
representative result of three independent experiments is shown. (B)
Fibronectin mRNA levels quantitated by scanning densitometry and
corrected for the level of GAPDH in the same samples are shown
relative to the level in untreated cells (1.0). (C) Calphostin C and
Rottlerin blocked the EGF-mediated upregulation of fibronectin mRNA
expression in a concentration-dependent manner. Human dermal
fibroblasts were serum starved for 24 h and treated with 20 or 100
mM Calphostin C, 1 or 3 mM Rottlerin for 1 h prior to the addition of 20
ng per mL of EGF for 24 h. Northern blot analysis was performed to
evaluate the fibronectin mRNA expression. Levels of GAPDH mRNA
are shown as a loading control. One representative result of three
independent experiments is shown. (D) Fibronectin mRNA levels
quantitated by scanning densitometry and corrected for the level of
GAPDH in the same samples are shown relative to the level in untreated
cells (1.0). po0.05, as compared with the value in untreated cells.
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EGF-mediated fibronectin expression, we investigated
whether EGF could induce these PKC isozymes in human
dermal fibroblasts. The level of PKCd increased as early as
30 min after the addition of EGF, gradually increased, and
maximally elevated at 60 min (2.5-fold) (Fig 7A and B). But
EGF did not change the amount of PKCa or PKCe in human
dermal fibroblasts. This result suggested that EGF selec-
tively induces PKCd in human dermal fibroblasts.
Next, we examined whether EGF treatment changes the
cellular localization of PKCd using immunofluorescence
analysis. As shown in Fig 8, staining at the cell periphery
increased 60 min after exposure to 20 ng per mL EGF,
whereas staining slightly decreased in the cytoplasm. This
suggested that EGF translocates PKCd to the membrane.
Rottlerin inhibits EGF-mediated upregulation of the
stability of ﬁbronectin mRNA We determined how effec-
tively EGF upregulates the stability of fibronectin mRNA and
whether Rottlerin inhibits EGF-mediated upregulation of the
stability of fibronectin mRNA. Human dermal fibroblasts
were treated with 20 ng per mL EGF in the presence or
absence of Rottlerin (pre-treated 1 h prior to the addition of
EGF) for 12 h, and then transcription was terminated by the
addition of 400 ng per mlactinomycin D. Eight and 12 h after
the termination of transcription, the loss of EGF-induced
fibronectin mRNA was significantly less than that observed
in the untreated cells. But there was no significant
difference in the loss of fibronectin mRNA between
untreated cell and the cell treated with EGF and Rottlerin
(Fig 9A and B). This suggested that Rottlerin inhibits EGF-
mediated upregulation of fibronectin mRNA expression by
blocking EGF-mediated downregulation of its degradation
rate.
Discussion
This report is about how EGF regulates fibronectin expres-
sion in human dermal fibroblasts. Our results indicate that
the EGF-induced increase in fibronectin mRNA expression
was controlled at the level of post-transcription. Blocking
mRNA synthesis with actinomycin D did not completely
abrogate the EGF-induced fibronectin upregulation. Induc-
tion of fibronectin mRNA by EGF was observed in the
presence of cycloheximide, indicating that de novo protein
synthesis is not required for this response. The treatment
with EGF significantly reduced the degradation rate of the
fibronectin mRNA. Moreover, EGF did not significantly
change the fibronectin promoter activity. These results
suggested that EGF induces fibronectin expression in
human dermal fibroblasts at the level of post-transcription.
Our study is partially contradicted by the results of Lee et al
(2000), which demonstrated that PKC activation increased
FN promoter activity in hepatoma cells. This discrepancy is
probably because different cells were used.
Several studies using different systems have highlighted
the importance of PKC in cell adhesion and spreading (Vuori
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Figure 6
Effect of protein kinase C (PKC) inhibitors or dominant-negative
PKCd on epidermal growth factor (EGF)-induced fibronectin
protein expression. (A) Calphostin C and Rottlerin blocked the EGF-
mediated upregulation of fibronectin protein expression in a concen-
tration-dependent manner. Medium samples (adjusted by counting cell
numbers) were subjected to immunoblotting with anti-fibronectin
antibodies. One representative result of three independent experiments
is shown. (B) Transfection with dominant-negative mutant form of PKCd
blocked the EGF-mediated induction of fibronectin expression. Human
dermal fibroblasts were transiently transfected with either empty vector
or with dominant-negative mutant constructs for PKCd. After incuba-
tion overnight, the transfected cells were either treated or untreated
with 20 ng per mL EGF for 48 h. Medium samples (adjusted by counting
cell numbers) were subjected to immunoblotting with anti-fibronectin
antibodies. One representative result of three independent experiments
is shown. Data are expressed as the mean  SD of three independent
experiments.
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Figure7
Upregulation of protein kinase C (PKC)d signaling pathway by
epidermal growth factor (EGF) in human dermal fibroblasts. Human
dermal fibroblasts were serum starved for 24 h and treated with 20 ng
per mL EGF for the indicated times. (A) Cell lysates (30 mg of protein per
sample) were subjected to immunoblotting with anti-PKCa, PKCd, or
PKCe antibodies. That the total amounts of proteins were unchanged
was confirmed by immunoblotting using anti-b-actin antibodies. One
representative result of three independent experiments is shown. (B)
The levels of PKCa, PKCd, or PKCe quantitated by scanning
densitometry and corrected for the levels of b-actin in the same
samples are shown relative to the level at 0 h (1.0). Data are expressed
as the mean  SD of three independent experiments. po0.05, as
compared with the value in untreated cells.
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and Ruoslahti, 1993; Schlaepfer et al, 1994; Disatnik and
Rando, 1999). In addition, numerous studies have shown
that activation of the EGF receptor leads to increased cell
motility partially via PKC signaling pathway (Chen et al,
1994). The PKC family, which is known to be activated by
EGF or stimulation of EGF receptor in various cells
([34]Mitchell et al, 1996; Judith et al, 1998), can be classified
into three major families (Ron and Kazanietz, 1999). The
classical PKC consist of PKCa, bI, bII, and g, which are
Ca2þ /diacylglycerol-dependent kinases. The novel PKC
consist of PKCd, e, Z, and y, which are Ca2þ -independent
but require diacylglycerol for activation. The third family,
atypical PKCs, consist of PKCi/l and z, which are neither
Ca2þ nor diacylglycerol dependent. The PKC isozymes
responsible for mediating cell attachment may be tissue
and stimulus specific. Studies in different cell types have
demonstrated PKCa, d, and e localization to focal adhesions
(Liao and Jaken, 1993; Haimovich et al, 1996; Haller et al,
1998). Moreover, numerous studies using various types of
cells have demonstrated that PKCd signaling is involved in
cell migration, which plays an important role in wound
healing (Andre et al, 1999; Li et al, 2002; Choe et al, 2003). In
this study, we demonstrated that the PKCd signaling
pathway is required for EGF-induced upregulation of
fibronectin expression, as indicated by the facts that
Calphostin C and Rottlerin blocked the increase in
fibronectin mRNA and protein expression by the EGF
treatment. Rottlerin has been reported to be a selective
PKCd inhibitor (Gschwendt et al, 1994), although several
authors reported to the contrary (Davies et al, 2000; Soltoff,
2001). Therefore, we used another reagent (Calphostin C)
and plasmid (dn mutant form of PKCd) to determine the
signaling pathway. Probably, the activation of ERK or p38
MAPK is unnecessary for EGF-mediated upregulation of
fibronectin synthesis because neither PD98059 (MEK
inhibitor) nor SB203580 (p38 MAPK inhibitor) inhibited
fibronectin expression induced by EGF. In contrast to our
study, Uchiyama-Tanaka et al (2001) reported that the
activation of ERK or p38 MAPK signaling pathway also
upregulates fibronectin expression in mesangial cells. But
like in our study, they also demonstrated that Calphostin
C inhibited fibronectin expression more potently than
PD98065 or SB203580. This minor difference may derive
from the difference of the used cells. These observations
that EGF-mediated induction of fibronectin expression is
inhibited by the expression of a dominant-negative form of
PKCd indicated that PKCd signaling pathway appears to
participate in the regulation of fibronectin protein synthesis.
In addition, the pre-treatment of cells with Rottlerin
significantly attenuated the EGF-induced reduction of
fibronectin mRNA degradation rate. Taken together, these
results indicate that EGF-mediated induction of fibronectin
Figure 8
Effects of epidermal growth factor (EGF) on localization of protein
kinase C (PKC)d in human dermal fibroblasts. The localization of
PKCd was investigated with immunofluorescence analysis using human
dermal fibroblasts as described in Materials and Methods. PKCd was
located mainly in the cytoplasm of fibroblasts without stimulation (A).
PKCd was translocated to the membrane 60 min after exposure to 20
ng per mL EGF (B).
Figure9
Effect of Rottlerin on the epidermal growth factor (EGF)-induced
upregulation of fibronectin mRNA stability. Human dermal fibro-
blasts were serum starved for 24 h and incubated in the absence (a) or
presence of 20 ng per mL EGF (b) or EGF plus 3 mM Rottlerin (c) for 12 h
before the addition of 400 ng per mL actinomycin D. (A) Northern blot
analysis was performed to evaluate fibronectin mRNA expression in
the cells with no treatment (a), only with 20 ng per mL EGF (b), or with
EGF plus 3 mM Rottlerin (c). Levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA are shown as a loading control. One
representative result of three independent experiments is shown. (B)
Time-dependent degradation of fibronectin mRNA. The corrected
density was expressed as a percent of the value at time 0. The
squares with dashed line indicate the EGF-treated cells, and the filled
circles with continuous line indicate control (untreated) cells and the
open circles with irregularly dashed line indicate the cells treated
with EGF and Rottlerin-treated levels. Data are expressed as the
mean  SD of three independent experiments. po0.05 as compared
with the value in untreated cells.
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expression is regulated at the post-transcription level via
PKCd signaling pathway. As seen in Figs 7 and 8, EGF
enhanced PKCd protein levels in a rather short time.
Although few authors clearly stated that PKCd protein
levels are so rapidly enhanced, some published reports
showed that PKC protein levels rapidly increase (Runyan
et al, 2003). Several authors have reported that fibronectin
expression is dependent on PKC signaling pathways under
various conditions (Lee et al, 1996; Kucich et al, 2000;
Uchiyama-Tanaka et al, 2001; Li et al, 2002; Twigg et al,
2002). This report demonstrates that PKCd mediates EGF-
induced fibronectin expression in human dermal fibroblasts.
In conclusion, we showed that EGF upregulates fibro-
nectin expression at the post-transcriptional level mainly by
reducing the rate of fibronectin mRNA degradation, and we
demonstrated that PKC signaling pathway is essential for
the EGF-mediated induction of fibronectin expression.
These results will make some contribution to a better under-
standing of the complex mechanism of wound healing.
Materials and Methods
Reagents Calphostin C, Rottlerin, Go¨6976, PD98059, and
SB203580 were purchased from Calbiochem (La Jolla, California).
Recombinant human EGF was obtained from R & D Systems
(Minneapolis, Minnesota). Actinomycin D and cycloheximide were
purchased from Sigma (St. Louis, Missouri). The luciferase assay
kit was purchased from Promega (Madison, Wisconsin). Anti-
fibronectin antibodies and anti-protein kinase C (anti-PKC)d
antibodies for immunofluorescent staining were obtained from
Santa Cruz Biotechnology (Santa Cruz, California). Anti-PKCa,
PKCd, and PKCe antibodies for immunoblotting were from Upstate
Biotechnology (Lake Placid, New York). Anti-b actin antibodies
were from Sigma. FuGENE 6 was obtained from Roche Diagnos-
tics (Indianapolis, Indiana).
Cell cultures Fibroblasts were obtained by skin biopsy of five
healthy donors. All biopsies were obtained with informed consent
and institutional approval. The study was conducted according to
the declaration of the Helsinki principles. Primary explant cultures
were established in 25-cm2 culture flasks in MEM supplemented
with 10% FBS, 2 mM glutamine, and 50 mg per mL gentamycin, as
described previously (Ihn et al, 1996, 1997). Monolayer cultures
were maintained at 371C in 5% CO2 in air. Fibroblasts between the
third and sixth subpassages were used for experiments.
Cell lysis, immunoblotting For detection of fibronectin, the
culture medium was collected, and the loading amount was
adjusted by the number of cells or protein concentrations of cell
lysates determined by using a Bio-Rad (Hercules, California)
protein assay, as recommended by the manufacturer. Proteins
were subjected to SDS–polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes. Membranes were incu-
bated overnight with anti-fibronectin antibody (1:500 dilution),
washed, and incubated with a secondary antibody against rabbit
IgG for 60 min. After washing, visualization was performed by
enhanced chemiluminescence (Amersham Pharmacia Biotech, UK).
For detection of PKCs, fibroblasts were washed with PBS at
41C and solubilized in lysis buffer containing 50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 50 mM sodium
fluoride, 1 mM sodium orthovanadate and 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), as described previously (Ihn et al, 1996,
1997). As a loading control, immunoblotting was also performed
using antibodies against b-actin (1:2000 dilution).
Immunoﬂuorescence Immunofluorescence analysis was per-
formed as described previously (Ihn and Tamaki, 2002). In brief,
normal dermal fibroblasts were cultured in four-well tissue culture
chamber slides. After cells were placed under conditions of serum
starvation for 24 h and treated with 20 ng per mL EGF for an
additional 1 h, the medium was removed and the cells were
washed with PBS and fixed in 3.7% formaldehyde/PBS for 10 min.
After two washes with PBS, cells were incubated for 30 min in PBS
containing 10% FBS. Cells were permeabilized with 0.5% Triton-X.
An antibody against PKCd was added and the slides were
incubated for 1 h at 371C. After three washes, a fluorescein-
conjugated secondary antibody was added and the slides were
incubated for 1 h at 371C.
RNA preparation and northern blot analysis Total RNA was
extracted using an acid guanidinium thiocyanate–phenol–chloro-
form method (Ihn et al, 1996, 1997). RNA samples were subjected
to electrophoresis on 1% agarose/formaldehyde gels and blotted
onto nylon filters (Roche Diagnostics). The filters were UV cross-
linked, prehybridized, and sequentially hybridized with DNA probes
for fibronectin and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The membranes were then washed and exposed to
X-ray film.
Plasmids The plasmid-containing fibronectin promoter region
(508/þ 18), which was inserted into the lucifease vector
pGL3basic (Promega), was kindly provided by Dr Mitsuhiro Suzuki
(Suzuki et al, 1998). The dominant-negative (dn) mutant form of
PKCd was kindly provided by Dr Weiqun Li (Li et al, 1996).
Plasmids used in transient transfection assays were purified twice
on CsCl gradients, as described previously (Ihn et al, 1997). At
least two different plasmid preparations were used for each
experiment.
Transient transfection and luciferase assays For each transfec-
tion, 2 mg of fibronectin promoter-pGL3basic, 1 mg of b-
galactosidase (transfection efficiency control) and FuGENE 6 were
combined and added to cells. Transfected cells were treated for 18
h with EGF in serum-free MEM before cell lysis in 50 mL of Reporter
Lysis Buffer (Promega). Luciferase activity was normalized by co-
transfected b-galactosidase activity to correct for the transfection
efficiency. All transfections were repeated at least three times.
Statistical analysis Data presented as bar graphs are the
means  SD of at least three independent experiments. Statistical
analysis was performed by the Mann–Whitney U test. p values less
than 0.05 were considered significant.
We thank Dr M. Suzuki for kindly providing fibronectin promoter
luciferase constructs. We thank Dr Li Weiqun for kindly providing
dominant-negative mutant form of PKCd.
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